Literature DB >> 28687205

Oxindole-based intraocular pressure reducing agents.

Ekaterina V Zaryanova1, Nataly A Lozinskaya2, Olga V Beznos3, Maria S Volkova2, Nataly B Chesnokova3, Nikolay S Zefirov2.   

Abstract

The study represents the new findings at the crossroads of chemistry and medicine, particularly between medicinal and organic chemistry and ophthalmology. In this work we describe how the chemical reactivity of indolinone scaffold may be used to create small molecule ligands with strong biological response comparable with and larger than that of endogenous hormone. The synthesis of oxindole-based melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) analogues was proposed and their ability to influence intraocular pressure (IOP) was studied in vivo. Time-dependent study revealed the prolonged effect (more than 6h) of the lead-compound. This effect in combination with high IOP reducing effect (41±6%) in low concentrations of the active compound (0.1wt%) and with high water solubility represents a great potential of low-cost oxindole derivatives as potent antiglaucoma agents.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glaucoma treatment; Intraocular pressure; Melatonin; Oxindole derivatives

Mesh:

Substances:

Year:  2017        PMID: 28687205     DOI: 10.1016/j.bmcl.2017.06.065

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Preliminary Discovery of Small Molecule Inhibitors of Epidermal Growth Factor Receptor (EGFR) That Bind to the Extracellular Domain.

Authors:  Rosa Di Liddo; Marco Verona; Christian Vaccarin; Laura Acquasaliente; Sandra Schrenk; Monica Piccione; Carola Cenzi; Michele De Franco; Matteo Dal Prà; Giovanni Ribaudo; Maria Grazia Ferlin; Maria Teresa Conconi; Adriana Chilin; Valentina Gandin; Giovanni Marzaro
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.